Angioimmunoblastic T-Cell Lymphoma: Treatment Options

Patients with AITL may be treated with a steroid that can temporarily relieve the symptoms caused by the immune system’s reaction to the cancer cells, such as joint inflammation or pain and skin rash.

Recommended first-line therapy is either a clinical trial or a multiagent chemotherapy regimen, such as CHOP (cyclophosphamide doxorubicin, vincristine, and prednisone). Sometimes higher doses of chemotherapy followed by stem cell transplantation may be added to multiagent chemotherapy.

Several drugs have been tested in small clinical trials (alone or in combination with current chemotherapy regimens) and show promise for the treatment of AITL, including:

• Brentuximab vedotin (Adcetris)
• Lenalidomide (Revlimid)
• Panobinostat (Farydak)

To learn more about angioimmunoblastic T-cell lymphoma, download the AITL Factsheet.

See also:

• Clinical Trials Fact Sheet
• Understanding Cell Therapy Guide